Matches in SemOpenAlex for { <https://semopenalex.org/work/W2331509632> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W2331509632 abstract "In this article, recommendations from the 2012 American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) position statement are discussed with an emphasis on the appropriate use of Dipeptidyl Peptidase-4 (DPP-4) inhibitors in individuals with Type 2 Diabetes Mellitus (T2DM). The 2012 ADA/EASD position statement emphasizes individualization of treatment, with glycated hemoglobin (A1C) targets being determined for each patient based on life expectancy, complications, disease duration, comorbidities, such as cardiovascular disease or cognitive impairment, and the risk of hypoglycemia and other adverse events. Patients’ attitudes and support systems should also be considered. Recommendations for pharmacotherapy are less prescriptive and should be based on a patient’s needs, preferences, and tolerances. In general, metformin is recommended as firstline therapy for most patients, although combination of 2 noninsulin agents or insulin alone should be considered in patients with baseline A1C ≥ 9.0%. Add-on therapy to metformin will likely be needed to achieve and maintain glycemic control as the disease progresses. It is important to avoid therapies that increase the risk of weight gain or and, especially in older patients, hypoglycemia. As discussed in this review, DPP-4 inhibitors are well tolerated and effectively lower A1C and improve β-cell function without increasing the risk of hypoglycemia and weight gain. DPP- 4 inhibitors are recommended as an option for first-line therapy when metformin is contraindicated or not tolerated and are also recommended as an option for add-on therapy to metformin and to metformin plus a sulfonylurea, a thiazolidinedione, or insulin. This article reviews the appropriate use of DPP-4 inhibitors in individuals with T2DM and recently published cardiovascular outcome trials with DPP-4 inhibitors." @default.
- W2331509632 created "2016-06-24" @default.
- W2331509632 creator A5090784160 @default.
- W2331509632 date "2014-01-01" @default.
- W2331509632 modified "2023-09-28" @default.
- W2331509632 title "Type 2 Diabetes Treatment Recommendations Update: Appropriate Use of Dipeptidyl Peptidase-4 Inhibitors" @default.
- W2331509632 doi "https://doi.org/10.4172/2155-6156.1000414" @default.
- W2331509632 hasPublicationYear "2014" @default.
- W2331509632 type Work @default.
- W2331509632 sameAs 2331509632 @default.
- W2331509632 citedByCount "3" @default.
- W2331509632 countsByYear W23315096322017 @default.
- W2331509632 countsByYear W23315096322018 @default.
- W2331509632 countsByYear W23315096322023 @default.
- W2331509632 crossrefType "journal-article" @default.
- W2331509632 hasAuthorship W2331509632A5090784160 @default.
- W2331509632 hasBestOaLocation W23315096321 @default.
- W2331509632 hasConcept C126322002 @default.
- W2331509632 hasConcept C134018914 @default.
- W2331509632 hasConcept C156490143 @default.
- W2331509632 hasConcept C181199279 @default.
- W2331509632 hasConcept C2777180221 @default.
- W2331509632 hasConcept C2778763485 @default.
- W2331509632 hasConcept C2781469919 @default.
- W2331509632 hasConcept C55493867 @default.
- W2331509632 hasConcept C555293320 @default.
- W2331509632 hasConcept C60644358 @default.
- W2331509632 hasConcept C71924100 @default.
- W2331509632 hasConcept C86803240 @default.
- W2331509632 hasConcept C98274493 @default.
- W2331509632 hasConceptScore W2331509632C126322002 @default.
- W2331509632 hasConceptScore W2331509632C134018914 @default.
- W2331509632 hasConceptScore W2331509632C156490143 @default.
- W2331509632 hasConceptScore W2331509632C181199279 @default.
- W2331509632 hasConceptScore W2331509632C2777180221 @default.
- W2331509632 hasConceptScore W2331509632C2778763485 @default.
- W2331509632 hasConceptScore W2331509632C2781469919 @default.
- W2331509632 hasConceptScore W2331509632C55493867 @default.
- W2331509632 hasConceptScore W2331509632C555293320 @default.
- W2331509632 hasConceptScore W2331509632C60644358 @default.
- W2331509632 hasConceptScore W2331509632C71924100 @default.
- W2331509632 hasConceptScore W2331509632C86803240 @default.
- W2331509632 hasConceptScore W2331509632C98274493 @default.
- W2331509632 hasIssue "08" @default.
- W2331509632 hasLocation W23315096321 @default.
- W2331509632 hasOpenAccess W2331509632 @default.
- W2331509632 hasPrimaryLocation W23315096321 @default.
- W2331509632 hasRelatedWork W2045545354 @default.
- W2331509632 hasRelatedWork W2053043791 @default.
- W2331509632 hasRelatedWork W2089358760 @default.
- W2331509632 hasRelatedWork W2778185458 @default.
- W2331509632 hasRelatedWork W2792609591 @default.
- W2331509632 hasRelatedWork W2809613659 @default.
- W2331509632 hasRelatedWork W4302550252 @default.
- W2331509632 hasRelatedWork W4323542466 @default.
- W2331509632 hasRelatedWork W86081567 @default.
- W2331509632 hasRelatedWork W1543637879 @default.
- W2331509632 hasVolume "05" @default.
- W2331509632 isParatext "false" @default.
- W2331509632 isRetracted "false" @default.
- W2331509632 magId "2331509632" @default.
- W2331509632 workType "article" @default.